<DOC>
	<DOCNO>NCT02589860</DOCNO>
	<brief_summary>This pilot study explore identify change molecular process within oral mucosa associate development oral mucositis ( OM ) patient treat Melphalan undergo autologous peripheral blood stem cell transplantation .</brief_summary>
	<brief_title>Analysis Oral Mucositis Patient 's Undergoing Melphalan Conditioning Autologous Stem Cell Transplant</brief_title>
	<detailed_description>This exploratory observational ( non-therapeutic ) study collect blood buccal mucosal sample evaluate RNA expression , assess bacterial colonization , plasma Melphalan concentration approximately 50 eligible patient . All study sample collect participant hospitalize receive standard care high-dose Melphalan ( HDM ) chemotherapy autologous peripheral blood stem cell transplantation ( ASCT ) . Patients receive treatment typically admit day HDM . The day HDM , patient receive ASCT remain hospitalized approximately 21 day , absolute neutrophil count increase least 500 cell per mm3 longer consider neutropenic . Patients blood sample collect pharmacokinetic analysis approximately 0 minute ( infusion begin ) , 15 minute ( infusion ) , 30 minute ( end infusion ) , 60 minute , 90 minute , 120 minute , 180 minute start Melphalan infusion . A buccal swab do collect mucosal bacterial sample use paper strip ( Periopaper ) sterile cotton tip swab brush right leave buccal mucosa approximately 15-30 second follow time point : 1 . Within 24 hour PRIOR administration Melphalan 2 . Day +3 AFTER transplantation 3 . Upon development OM ( approximately day +7-10 ) 4 . Upon recovery absolute neutrophil count ( ANC ) great 500/mm3 , discharge , whichever occur first , patient develop OM A buccal scrap do gene expression use dermatologic curette take right left buccal mucosa follow time point : 1 . Within 24 hour PRIOR administration Melphalan 2 . Day +3 AFTER transplantation Note : Patients ' mouth rinse Mary 's Magic mouthwash prior procedure 15 second , allow removal food particle , colonize bacteria anesthetization oral mucosa . During procedure , sign patient discomfort monitor . If patient express discomfort , additional oral topical anesthetic utilized de-sensitive buccal mucosa .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>1 . Patients multiple myeloma ( MM ) systemic lightchain amyloidosis receive highdose Melphalan ( HDM ) autologous peripheral blood stem cell transplantation ( ASCT ) . 2 . Age great 18 year old 3 . Patients receive total Melphalan dose 140200 mg/m2 preparative regimen 4 . No prior history allogeneic stem cell transplantation 5 . Patients otherwise meet standard institutional criterion ASCT 1 . Patients meet inclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Stem Cell Transplantation</keyword>
</DOC>